{"transactions":[{"id":1066791,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks section."}}],"security":"Tranche C Common Share Purchase Warrants","published_at":"2025-08-14T20:17:09.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-078631","document":"tm2523440-4_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925078631/tm2523440-4_4aseq1.xml","form_type":"4/A","original_submission_date":"2025-07-29"}},{"id":1066790,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks section."}}],"security":"Tranche B Common Share Purchase Warrants","published_at":"2025-08-14T20:17:09.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-078631","document":"tm2523440-4_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925078631/tm2523440-4_4aseq1.xml","form_type":"4/A","original_submission_date":"2025-07-29"}},{"id":1066789,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks section."}}],"security":"Tranche A Common Share Purchase Warrants","published_at":"2025-08-14T20:17:09.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-078631","document":"tm2523440-4_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925078631/tm2523440-4_4aseq1.xml","form_type":"4/A","original_submission_date":"2025-07-29"}},{"id":1066788,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks section."}}],"security":"Common Shares, no par value","published_at":"2025-08-14T20:15:35.000Z","date":"2025-03-13","kind":"other","planned":false,"acquired":false,"shares":48333,"ownership":{"direct":false,"nature":"By Title 19 Acies"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 13, 2025, the ownership of Title 19 Acies, a series of a Delaware limited liability company, was assigned to Skye Peak Partners LLC, a Delaware limited liability company (\"SPP\"), effective as of January 1, 2025. In connection with such assignment, the management of Title 19 Acies changed from the Reporting Person as sole manager to Emmett Gordon and Michael Youniss as managers, and the Reporting Person does not otherwise have investment control over the shares of the Issuer held by SPP. Accordingly, the Reporting Person no longer has a pecuniary interest in shares of the Issuer held by Title 19 Acies."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 13, 2025, the ownership of Title 19 Acies, a series of a Delaware limited liability company, was assigned to Skye Peak Partners LLC, a Delaware limited liability company (\"SPP\"), effective as of January 1, 2025. In connection with such assignment, the management of Title 19 Acies changed from the Reporting Person as sole manager to Emmett Gordon and Michael Youniss as managers, and the Reporting Person does not otherwise have investment control over the shares of the Issuer held by SPP. Accordingly, the Reporting Person no longer has a pecuniary interest in shares of the Issuer held by Title 19 Acies."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Acies, of which the Reporting Person was the sole manager."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-078615","document":"tm2523440-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925078615/tm2523440-2_4seq1.xml","form_type":"4"}},{"id":1080019,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Shares","published_at":"2025-07-30T00:20:23.000Z","date":"2025-07-29","kind":"purchase","planned":false,"acquired":true,"shares":539100,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":539100,"derivative":{"underlying":"Common Shares","underlying_shares":539100},"source":{"system":"sec-edgar","filing":"0001104659-25-071858","document":"tm2521929-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925071858/tm2521929-2_4seq1.xml","form_type":"4"}},{"id":1080018,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche C Common Share Purchase Warrants","published_at":"2025-07-30T00:20:23.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-071858","document":"tm2521929-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925071858/tm2521929-2_4seq1.xml","form_type":"4"}},{"id":1080017,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche B Common Share Purchase Warrants","published_at":"2025-07-30T00:20:23.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-071858","document":"tm2521929-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925071858/tm2521929-2_4seq1.xml","form_type":"4"}},{"id":1080016,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche A Common Share Purchase Warrants","published_at":"2025-07-30T00:20:23.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":false,"shares":119800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":345316,"derivative":{"underlying":"Common Shares","underlying_shares":119800},"source":{"system":"sec-edgar","filing":"0001104659-25-071858","document":"tm2521929-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925071858/tm2521929-2_4seq1.xml","form_type":"4"}},{"id":1080015,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-07-30T00:20:23.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":119800,"ownership":{"direct":false,"nature":"By Title 19 Promis"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":2435029,"source":{"system":"sec-edgar","filing":"0001104659-25-071858","document":"tm2521929-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925071858/tm2521929-2_4seq1.xml","form_type":"4"}},{"id":1080014,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-07-30T00:20:23.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":119800,"ownership":{"direct":false,"nature":"By Title 19 Promis"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":2315229,"source":{"system":"sec-edgar","filing":"0001104659-25-071858","document":"tm2521929-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925071858/tm2521929-2_4seq1.xml","form_type":"4"}},{"id":1080013,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-07-30T00:20:23.000Z","date":"2025-07-25","kind":"other","planned":false,"acquired":true,"shares":119800,"ownership":{"direct":false,"nature":"By Title 19 Promis"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":2195429,"source":{"system":"sec-edgar","filing":"0001104659-25-071858","document":"tm2521929-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925071858/tm2521929-2_4seq1.xml","form_type":"4"}},{"id":1096089,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2025-07-02T20:15:22.000Z","date":"2025-06-30","kind":"sale","planned":false,"acquired":false,"shares":93223,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2025, the reporting person contributed 93,223 shares of common stock of the Issuer held by the reporting person to Skye Peak Partners LLC, a Delaware limited liability company (\"SPP\"), in exchange for membership interests of SPP."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-065292","document":"tm2519639-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465925065292/tm2519639-1_4seq1.xml","form_type":"4"}},{"id":1403967,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2024-09-18T20:15:05.000Z","date":"2024-09-17","kind":"purchase","planned":false,"acquired":true,"shares":16292,"price":1.4,"value":22808.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in four separate transactions, with prices ranging from $1.37 to $1.40 for an average weighted purchase price of $1.40. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased in each transaction."}],"balance_after":93223,"source":{"system":"sec-edgar","filing":"0001104659-24-100976","document":"tm2424268-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465924100976/tm2424268-1_4seq1.xml","form_type":"4"}},{"id":1403966,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2024-09-18T20:15:05.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":76931,"price":1.2228,"value":94071.2268,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in forty-two separate transactions, with prices ranging from $1.1200 to $1.3700 for an average weighted purchase price of $1.2228 rounded to the nearest ten thousandth. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased in each transaction."}],"balance_after":76931,"source":{"system":"sec-edgar","filing":"0001104659-24-100976","document":"tm2424268-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465924100976/tm2424268-1_4seq1.xml","form_type":"4"}},{"id":1443263,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 2 Preferred Shares, no par value","published_at":"2024-08-02T20:15:15.000Z","date":"2024-07-31","kind":"exercise","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001104659-24-085371","document":"tm2420441-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465924085371/tm2420441-1_4seq1.xml","form_type":"4"}},{"id":1443262,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche C Common Share Purchase Warrants","published_at":"2024-08-02T20:15:15.000Z","date":"2024-07-31","kind":"purchase","planned":false,"acquired":true,"shares":465116,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Consists of 465,116 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Consists of 465,116 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Consists of 465,116 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Consists of 465,116 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants are currently exercisable and expire on July 31, 2029."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":465116,"derivative":{"underlying":"Common Shares","underlying_shares":465116},"source":{"system":"sec-edgar","filing":"0001104659-24-085371","document":"tm2420441-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465924085371/tm2420441-1_4seq1.xml","form_type":"4"}},{"id":1443261,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche B Common Share Purchase Warrants","published_at":"2024-08-02T20:15:15.000Z","date":"2024-07-31","kind":"purchase","planned":false,"acquired":true,"shares":465116,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Consists of 465,116 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Consists of 465,116 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Consists of 465,116 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Consists of 465,116 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":465116,"derivative":{"underlying":"Common Shares","underlying_shares":465116},"source":{"system":"sec-edgar","filing":"0001104659-24-085371","document":"tm2420441-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465924085371/tm2420441-1_4seq1.xml","form_type":"4"}},{"id":1443260,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche A Common Share Purchase Warrants","published_at":"2024-08-02T20:15:15.000Z","date":"2024-07-31","kind":"purchase","planned":false,"acquired":true,"shares":465116,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Consists of 465,116 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Consists of 465,116 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Consists of 465,116 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Consists of 465,116 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants are immediately exercisable beginning on the date that approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof is received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":465116,"derivative":{"underlying":"Common Shares","underlying_shares":465116},"source":{"system":"sec-edgar","filing":"0001104659-24-085371","document":"tm2420441-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465924085371/tm2420441-1_4seq1.xml","form_type":"4"}},{"id":1443259,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2024-08-02T20:15:15.000Z","date":"2024-07-31","kind":"exercise","planned":false,"acquired":true,"shares":500000,"ownership":{"direct":false,"nature":"By Title 19 Promis"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series 2 Preferred Shares involuntarily converted into Common Shares at a 1:1 ratio upon the closing of the Offering, which was a cumulative qualified equity financing in excess of $14 million."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":2075629,"source":{"system":"sec-edgar","filing":"0001104659-24-085371","document":"tm2420441-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465924085371/tm2420441-1_4seq1.xml","form_type":"4"}},{"id":1443258,"issuer":{"id":6643,"kind":"organization","name":"ProMIS Neurosciences Inc.","symbol":"PMN"},"owners":[{"id":76537,"kind":"person","name":"GORDON MICHAEL S","position":1,"cik":"0001034608","reported_name":"GORDON MICHAEL S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, no par value","published_at":"2024-08-02T20:15:15.000Z","date":"2024-07-31","kind":"purchase","planned":false,"acquired":true,"shares":465116,"ownership":{"direct":false,"nature":"By Title 19 Promis"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 31, 2024, Title 19 Promis acquired 465,116 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement the (\"Offering\") conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager."}],"balance_after":1575629,"source":{"system":"sec-edgar","filing":"0001104659-24-085371","document":"tm2420441-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034608/000110465924085371/tm2420441-1_4seq1.xml","form_type":"4"}}]}